Literature DB >> 993337

The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.

H L Nossel, M Ti, K L Kaplan, K Spanondis, T Soland, V P Butler.   

Abstract

Plasma fibrinopeptide A (FPA) concentrations were measured in clinical blood samples incubated in the collecting syringe for different time periods before addition to heparin and Trasylol, and the rate of in vitro generation of FPA was calculated as the mean increment in FPA concentration per minute over the linear portion of the generation curve. 36 normal individuals had a mean plasma FPA level of 0.64 +/- 0.56 pmol/ml and an FPA generation rate of less than 0.5 pmol/ml per min. Clinical samples with elevated plasma FPA levels manifested slow (less than 1 pmol/ml per min) (28 patients) or rapid FPA generation (greater than 1 pmol/ml per min) (33 patients). Slow FPA generation was found in 10/10 patients with venous thrombosis, in 4/4 with aortic aneurysm, and in several patients with acquired hypofibrinogenemia. In one such patient, addition of fibrinogen resulted in rapid FPA generation whereas thrombin addition was without effect. Rapid FPA generation was generally linear, was usually associated with slower fibrinopeptide B generation and was inhibited by parenteral or in vitro heparin. It is thought to reflect increased thrombin activity and was seen in patients with pulmonary embolism, active systemic lupus erythematosus, renal transplant rejection, and after infusion of prothrombin concentrates. The initial rate of FPA cleavage by thrombin at fibrinogen concentrations from 0.05 to 4 mg/ml showed little change between 2 and 4 mg/ml with a Km of 2.99 muM. At a fibrinogen concentration of 2.5 mg/ml the FPA cleavage rate was 49.2 +/- 1.6 nmol/ml per min per U of thrombin. Exogenous thrombin added to normal blood generated 21.7 nmol/ml per U of thrombin FPA in the first minute with a nonlinear pattern reflecting inactivation of thrombin and the presence of alternative substrates. Hence, the thrombin concentration in the blood cannot be calculated from the FPA generation rate. The FPA generation rates in clinical samples with rapid generation (1-28 pmol/ml per min) could be produced by 2 X 10(-5) to 5.6 X 10(-4) thrombin U/ml acting on purified fibrinogen at physiological conditions of pH, ionic strength, and temperature.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 993337      PMCID: PMC333281          DOI: 10.1172/JCI108566

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  [On the presence of neutral fats in normal and pathological human thrombocytes].

Authors:  G JEAN; L RACINE; R MARX; A GAUTIER
Journal:  Thromb Diath Haemorrh       Date:  1963-04-15

2.  HUMAN THROMBIN: ISOLATION AND STABILITY.

Authors:  K D MILLER; W H COPELAND
Journal:  Exp Mol Pathol       Date:  1965-08       Impact factor: 3.362

3.  A quick and accurate method for the determination of fibronogen in plasma.

Authors:  B C ELLIS; A STRANSKY
Journal:  J Lab Clin Med       Date:  1961-09

4.  Radioimmunoassay of fibrinopeptide A-clinical applications.

Authors:  C Kockum
Journal:  Thromb Res       Date:  1976-02       Impact factor: 3.944

5.  A new method for the determination of fibrinogen in small samples of plasma.

Authors:  O D RATNOFF; C MENZIE
Journal:  J Lab Clin Med       Date:  1951-02

6.  An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH.

Authors:  E F Plow; T S Edgington
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

7.  Plasma and serum antithrombin - III: differentiation by crossed immunoelectrophoresis.

Authors:  G Sas; D S Pepper; J D Cash
Journal:  Thromb Res       Date:  1975-01       Impact factor: 3.944

8.  Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes.

Authors:  P C Harpel; M W Mosesson
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

9.  Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood.

Authors:  A Z Budzynski; V J Marder
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

10.  Mechanisms for elevated fibrin/fibrinogen degradation products in acute experimental pulmonary embolism.

Authors:  J Cade; J Hirsh; E Regoeczi
Journal:  Blood       Date:  1975-04       Impact factor: 22.113

View more
  21 in total

1.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.

Authors:  K A Bauer; L M Weiss; D Sparrow; P S Vokonas; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

3.  Whole-genome sequencing study of serum peptide levels: the Atherosclerosis Risk in Communities study.

Authors:  Paul S de Vries; Bing Yu; Elena V Feofanova; Ginger A Metcalf; Michael R Brown; Atefeh L Zeighami; Xiaoming Liu; Donna M Muzny; Richard A Gibbs; Eric Boerwinkle; Alanna C Morrison
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

4.  Beta-thromboglobulin and fibrinopeptide A in diabetes mellitus as markers of vascular damage.

Authors:  M C Librenti; A D'Angelo; P Micossi; B Garimberti; P M Mannucci; G Pozza
Journal:  Acta Diabetol Lat       Date:  1985 Jan-Mar

5.  Lack of effect of cimetidine on action of phenprocoumon.

Authors:  J Harenberg; R Zimmermann; C Staiger; J X de Vries; E Walter; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

6.  Problems in the detection of carriers of hemophilia A: the influence of stress and thrombin.

Authors:  U Göbel; R von Kries; H Jürgens; H von Voss
Journal:  Blut       Date:  1978-07-14

7.  Formation of soluble fibrin oligomers in purified systems and in plasma.

Authors:  N Alkjaersig; A P Fletcher
Journal:  Biochem J       Date:  1983-07-01       Impact factor: 3.857

8.  Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.

Authors:  E M Conway; K A Bauer; S Barzegar; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

9.  Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets.

Authors:  T Fujimoto; S Ohara; J Hawiger
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

10.  Intracardiac mobile thrombus and D-dimer fragment of fibrin in patients with mitral stenosis.

Authors:  M Yasaka; K Miyatake; M Mitani; S Beppu; S Nagata; T Yamaguchi; T Omae
Journal:  Br Heart J       Date:  1991-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.